Abstract:Abstract Background Cystic fibrosis (CF) is a chronic multisystem disease with features including recurrent pulmonary infection, bronchiectasis, malnutrition, and alterations in drug metabolism which may discourage referral and listing for kidney transplantation. Although no specific renal phenotype is identified in CF, chronic kidney disease (CKD) occurs in young people and adults with CF with greater frequency than in the general population. The characteristics and outcomes of kidney transplantation in the CF population have not been previously described. Methods We used de-identified data supplied by the US Renal Data System (USRDS) to compare persons with end stage kidney disease (ESKD) with first kidney transplant, who did and did not have a diagnosis of CF. We compared demographic and clinical characteristics, mortality, patient survival, and death-censored graft survival using linear and logistic regression, multivariable logistic regression models, and Kaplan-Meier and log-rank tests with stratification/binning by propensity scores. Results Of those with dual diagnoses of CF and ESKD, half received a first kidney transplant. CF was independently associated with higher odds of receiving a living donor transplant. Those with a kidney transplant were younger than both those who did not have CF and those with CF without transplant and had higher odds of being female. Those with dual diagnoses of CF and ESKD had disproportionately lower odds of being identified as Black or African American relative to their representation in the population of all with CF and ESKD. Diabetes was more frequently a diagnosis and primary cause of ESKD in people with CF, but was approximately half as frequently the primary cause of ESKD as in those without CF. Complications of transplantation, particularly lung, were the second most frequent etiology of ESKD in people with CF. Overall survival with ESKD was 21.1 years for those with CF and 31.8 for those without CF. The survival benefit associated with transplant was 17.2 years for those with CF and 24.8 years for those without CF. Death censored median graft survival was significantly longer for those with CF, 20.4 vs 13.7 years. Conclusions CF is a chronic multisystem disease with features which may discourage referral and listing for kidney transplant. We used de-identified data from the USRDS datasets to describe the characteristics and outcomes of all unique individuals with the diagnosis of CF and first kidney transplant prevalent during the five-year period 2014 and 2018. Those with CF had similar odds to those without CF or receiving a first kidney transplant, and higher odds of receiving a living donor graft. Diabetes mellitus was significantly less frequently the primary cause of ESKD in those with CF and kidney transplant. Complications of solid organ transplant, particularly lung, were the second most frequent cause of ESKD in people with CF and kidney transplant. Median patient survival following the first kidney transplant was significantly shorter than for those who did not have CF, but was substantial, as was the survival advantage when compared to dialysis. Median graft survival was significantly longer for those with CF. It is our hope that this data will improve awareness of kidney disease in persons living with CF and their care teams, and encourage early referral to nephrology and transplant centers, and positive consideration of wait listing for kidney transplantation.

The Role of Cystic Fibrosis Transmembrane Conductance Regulator Modulators After Liver Transplantation in Persons With Cystic Fibrosis

Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients

Combined Liver-Lung-Kidney Transplant in a Patient with Cystic Fibrosis

Role of the Immune System in Liver Transplantation and Its Implications for Therapeutic Interventions

Attitudes toward and preparedness for lung transplantation among individuals with cystic fibrosis in the era of highly effective modulators

Outcomes of Kidney Transplantation in Cystic Fibrosis

Combined heterotopic liver-pancreas transplantation as a curative treatment for liver cirrhosis and diabetes mellitus in cystic fibrosis

Lung transplant list withdrawal in a liver transplant patient thanks to elexacaftor-tezacaftor-ivacaftor: a case report

Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients

Impact of CFTR Modulator Therapies on Liver Function in Cystic Fibrosis Patients: A Systematic Review of Hepatic Biomarkers

An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.

Regulatory T Cell Therapy Following Liver Transplantation

Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies

Challenges in the use of highly effective modulator treatment for cystic fibrosis

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment

Modifier genes in cystic fibrosis-related liver disease

Survival After Lung Transplant for Cystic Fibrosis in Portugal: A Single Center Experience

Peri‐operative and long‐term outcomes of kidney transplantation in patients with cystic fibrosis

Outcomes of single vs double lung retransplantation in patients with cystic fibrosis

An aging population of patients with cystic fibrosis undergoes lung transplantation: An analysis of the ISHLT Thoracic Transplant Registry

Pathophysiology of Cystic Fibrosis Liver Disease